Valerie D. Doodeman

FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration

Hazel Urwin, Keith A. Josephs, Jonathan D. Rohrer et al. · Acta Neuropathologica · 2010 · 249 citations · Full text

Medicine, Neurology, Pathology +11

Relationship between Single Nucleotide Polymorphisms and Haplotypes in <i>DPYD</i> and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

Maarten J. Deenen, Jolien Tol, Artur M Burylo et al. · Clinical Cancer Research · 2011 · 183 citations

Medicine, Genetics, Oncology +17

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide

Corine Ekhart, Valerie D. Doodeman, Sjoerd Rodenhuis et al. · Pharmacogenetics and Genomics · 2008 · 134 citations

Medicine, Pharmacokinetics, Pharmacology +17

Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel

Tessa M. Bosch, Alwin D. R. Huitema, Valerie D. Doodeman et al. · Clinical Cancer Research · 2006 · 125 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first‐line platinum‐gemcitabine chemotherapy

Markus Joerger, Sjaak A. Burgers, Egbert F. Smit et al. · Cancer · 2011 · 65 citations

Medicine, Oncology, Pharmacology +17